Novavax, Inc. (NVAX) said it has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals to develop Novavax's virus-like-particle-based vaccines against influenza in the country of Spain. This decision is due to the companies' inability to agree on acceptable terms of the proposed collaboration and to obtain the necessary funding commitments for the program.
Novavax is free to seek a new partner for its pandemic and seasonal influenza vaccine development efforts in Europe in the future.
For comments and feedback: editorial@rttnews.com